WILMINGTON, N.C.--(BUSINESS WIRE)--PPD, Inc. (Nasdaq:PPD) has been recognized for excellence in clinical research for the ninth consecutive year by pharmaceutical and biotech professionals surveyed for Life Science Leader magazine’s 2020 CRO Leadership Awards.
The awards honor contract research organizations (CROs) that meet or exceed their customers’ expectations, and this year, PPD earned recognition for its capabilities and quality in two small pharma categories. The company has pioneered the development, implementation and scaling of a purpose-built, customer-facing delivery model to address the specific needs of the growing biotechnology sector. PPD® Biotech is devoted to Phase I-IV clinical development solutions for biotech and small to midsize pharma companies.
“We combine PPD’s global reach and full-service capabilities with a hands-on approach, dedication and innovative mindset that drive the success of our rapidly growing customers,” said Daniel Burch, M.D., senior vice president and global head of PPD® Biotech. “Our expert teams prioritize companies of all sizes while leveraging full-scope expertise, resources and scalability.”
The magazine’s honor is based on survey responses from industry leaders with decision-making influence related to partnering with CROs. For the 2020 CRO Leadership Awards, Life Science Leader and Clinical Leader teamed with Industry Standard Research (ISR), a full-service pharmaceutical market research firm, to determine the award recipients. In all, 60 CROs were assessed this year on more than 20 performance metrics in ISR’s annual CRO Quality Benchmarking survey.
PPD is a leading global contract research organization providing comprehensive, integrated drug development, laboratory and lifecycle management services. Our customers include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 46 countries and approximately 24,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a firm commitment to quality to help customers bend the cost and time curve of drug development and optimize value in delivering life-changing therapies to improve health. For more information, visit www.ppd.com.
This news release contains forward-looking statements. These statements often include words such as “expect,” “believe,” “project,” “forecast,” “estimate,” “target” and other similar expressions. Although we believe these forward-looking statements are based on reasonable assumptions at the time they are made, you should be aware that many factors could affect our actual financial results, and therefore actual results might differ materially from those expressed in the forward-looking statements. Factors that might materially affect such forward-looking statements include, but are not limited to, the fragmented and highly competitive nature of the drug development services industry; changes in trends in the biopharmaceutical industry; our ability to keep pace with rapid technological changes that could make our services less competitive or obsolete; political, economic and/or regulatory influences and changes; and other factors disclosed under the “Risk Factors” section in our periodic reports filed with the Securities and Exchange Commission (SEC), including our latest Annual Report on Form 10-K and Quarterly Report on Form 10-Q which is available on our website at https://investors.ppd.com or the SEC’s website at www.sec.gov. We assume no obligation and disclaim any duty to revise or update any forward-looking statements, or make any new forward-looking statement, whether as a result of new information, future events or otherwise, except as required by applicable law.